Today: 19 May 2026
PetroChina A shares rise on Dalian refinery restart report — what matters before Monday
31 January 2026
1 min read

PetroChina A shares rise on Dalian refinery restart report — what matters before Monday

Shanghai, Feb 1, 2026, 03:24 (GMT+8) — Market closed

  • On Friday, PetroChina’s Class A shares on the Shanghai exchange closed 1.2% higher, finishing at 11.02 yuan.
  • Traders are reacting to a report that China National Petroleum Corporation plans to restart part of its Dalian refinery to handle discounted Russian crude.
  • All eyes on oil trends and macro signals next week, as OPEC+ meets Sunday and new China activity data rolls in.

PetroChina A shares (601857) closed Friday at 11.02 yuan, gaining 1.19% after dipping as low as 10.74 yuan and rising to 11.15 yuan during the day. The Shanghai index, meanwhile, dropped roughly 1% in the session.

The stock has reappeared on the oil tape. Investors are watching two key factors: any shifts in the company’s refining outlook, and if crude’s recent rally can sustain momentum into next week.

The focus on refining intensified after sources revealed CNPC is gearing up to restart a 200,000-barrel-per-day crude distillation unit at its Dalian refinery, offline since July. The move, still under wraps, involves tapping into discounted Russian-linked crude and hinges on approval from China’s National Development and Reform Commission, the sources added.

State oil giants usually track crude and policy news closely. Still, attention will turn to whether this signals a wider trend affecting peers like Sinopec and CNOOC, whose upstream and downstream operations differ significantly.

Crude markets look crowded in the near term. Prices have held above $70 a barrel, buoyed by ongoing U.S.-Iran tensions. OPEC+ officials indicated they will probably maintain their freeze on output increases at their Sunday meeting.

Aside from weekend headline risks, forecasters continue to expect a market dominated by surplus barrels. A Reuters poll put Brent at an average of $62.02 a barrel in 2026, with U.S. crude seen at $58.72, despite Brent trading near $70 on Jan. 30. Julius Baer’s Norbert Ruecker described the oil market as “in a lasting surplus,” while Cyrus De La Rubia of Hamburg Commercial Bank suggested OPEC+ will likely “defend a price floor.” Reuters

Macro factors weigh on PetroChina bulls. China’s official purchasing managers’ index (PMI), a key monthly gauge of business activity, dipped to 49.3 in January from 50.1, slipping into contraction territory. The non-manufacturing PMI fell to 49.4. Ting Lu, chief China economist at Nomura, warned that “Beijing will have to do much more” in the months ahead to keep annual growth above 4.5% in 2026. Investors are also eyeing the private-sector RatingDog PMI, set for release on Feb. 2. Reuters

This could get complicated fast. The Dalian restart still requires regulatory sign-off and might be delayed. A rebound in discounted crude shipments risks clashing with evolving sanctions enforcement or shipping bottlenecks. Plus, crude prices could easily lose ground if the geopolitical premium eases or OPEC+ throws the market a curveball.

PetroChina A shares start trading again Monday. The Shanghai market then pauses from Feb. 15 to 23 for the Spring Festival, reopening on Feb. 24 — a schedule likely to influence liquidity and positioning early in the month.

Stock Market Today

  • Q1 Earnings Review: Knowles Outshines Peers in Electronic Components Sector
    May 19, 2026, 6:20 AM EDT. Electronic components & manufacturing sector posted strong Q1 results, with revenues beating analysts' consensus by 3.8% and share prices rising 11% on average. Knowles (NYSE:KN) led within the group, reporting $153.1 million in revenues, up 15.8% year-on-year, surpassing expectations by 3.9%. CEO Jeffrey Niew highlighted solid revenue and earnings per share (EPS) performance. Knowles shares gained 13.4% post-earnings, trading at $35.45. TTM Technologies (NASDAQ:TTMI) posted the best overall quarter with revenues up 30.4%, beating estimates by 6.9%, and shares climbing 16% to $159.48. Sector growth prospects include expanding demand in automotive, healthcare, aerospace, and computing. Risks remain from geopolitical tensions and environmental regulations. Analysts remain cautious but optimistic on the sector outlook.

Latest articles

Hesai Up Premarket After Mercedes Lidar Win, Q1 Profit

Hesai Up Premarket After Mercedes Lidar Win, Q1 Profit

19 May 2026
Hesai Group shares rose 2.68% to $22.60 in U.S. premarket trading after reporting a first-quarter profit and confirming it will supply lidar sensors for Mercedes-Benz Level 3 autonomous models. The company shipped 471,723 lidar units, up 140.9% year-on-year, and posted revenue of RMB680.6 million ($98.7 million). Net income reached RMB18.3 million, reversing a loss from a year earlier.
Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

19 May 2026
Virax Biolabs shares surged 53.1% Monday to $0.2350 and climbed another 17.1% in early Tuesday premarket trading, hitting $0.2751. The rally followed a paid RedChip TV appearance and a May 15 ownership filing showing Armistice Capital with a 4.99% stake. No new clinical or product updates were posted. Trading volume Monday reached about 765.2 million shares.
Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

Amesite Shares Rise Premarket After NurseMagic Signs Largest Client

19 May 2026
Amesite Inc. shares surged 218% to $2.50 in premarket trading after announcing its largest NurseMagic deployment with a 2,700-patient home-care client. The company disclosed $83,332 in quarterly revenue and a $678,061 net loss, with cash at $740,711 before a $2.2 million April financing. Amesite did not reveal the new contract’s value or customer name. Its latest filing cited “substantial doubt” about ongoing operations.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Lam Research Corporation stock drops 6% into the weekend: what LRCX traders watch next
Previous Story

Lam Research Corporation stock drops 6% into the weekend: what LRCX traders watch next

Shell share price slips as buyback wraps up; earnings on deck next week
Next Story

Shell share price slips as buyback wraps up; earnings on deck next week

Go toTop